NCT05252572

Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies

Clinical Study on the Safety and Effectiveness of CLL1 CAR-T Cells in the Treatment of CLL1-positive Hematological Malignancies

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Clinical Study on the Safety and Effectiveness of CLL1 CAR-T Cells in the Treatment of CLL1-positive Hematological Malignancies

Detailed description

Human C-type lectin-like molecule 1 (CLL1) is a type II transmembrane glycoprotein ，CLL1 expression is restricted to bone marrow cells and most AML blasts. In addition, CLL1 is expressed in leukemia stem cells (LSC) but not in hematopoietic stem cells (HSC), may provide a potential therapeutic target for the treatment of AML.The CAR-T cell injection uses immune cells from healthy donors, and is the final product obtained after CAR genetic modification, cell expansion, culture, screening, preparation, sub-packaging, and release inspection. The center intends to apply for a clinical trial of CLL1 CAR-T cells to treat CLL1-positive hematological malignancies on the basis of preliminary research.

Conditions

• AML

Interventions

Type	Name	Description
BIOLOGICAL	CLL1 CAR T-cells	Drug: CLL1 CAR T-cells Each subject receive CLL1 CAR T-cells by intravenous infusion Other Name: CLL1 CAR T-cells injection

Timeline

• Start date: 2022-02-28
• Primary completion: 2024-11-30
• Completion: 2024-11-30
• First posted: 2022-02-23
• Last updated: 2022-02-23

Locations

2 sites across 1 country: China